Cisplatin-Associated Nephrotoxic Effects in Children

Menée au Canada à partir de données portant sur 159 enfants atteints d’un cancer (âge : inférieur ou égal à 18 ans), cette étude de cohorte prospective analyse les facteurs associés au risque d’insuffisance rénale aiguë en lien avec un traitement par cisplatine

Résumé en anglais

Cisplatin has been an important component of chemotherapy for cure and control of several pediatric and adult malignant tumors. Nephrotoxic effects of cisplatin are a limitation of cisplatin-based chemotherapy and are often prohibitive of further treatment with cisplatin, when they occur. However, this adverse effect is not uniformly manifested among all patients who receive cisplatin-based chemotherapy.1 During the past few decades, investigators have attempted to identify risk factors that predispose certain patients to nephrotoxic effects of cisplatin while sparing others. Interindividual variability in kidney injury associated with cisplatin is greater than that explained by pharmacokinetic differences among patients.2 What, if anything, can practitioners at the point of care do to ameliorate this risk of cisplatin-associated acute kidney injury (AKI) and subsequent chronic kidney disease while preserving the anticancer benefit?